These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38415009)

  • 21. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
    Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study.
    Dan JQ; Zhang YJ; Huang JT; Chen MS; Gao HJ; Peng ZW; Xu L; Lau WY
    Eur J Surg Oncol; 2013 Aug; 39(8):865-72. PubMed ID: 23597497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
    Hu X; Li R; Li Q; Zang M; Yuan G; Chen J
    BMC Infect Dis; 2022 Jul; 22(1):614. PubMed ID: 35836207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
    Shen J; Wang X; Wang N; Wen S; Yang G; Li L; Fu J; Pan X
    Front Cell Infect Microbiol; 2023; 13():1179689. PubMed ID: 37197205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib.
    Hsiao YW; Sou FM; Wang JH; Chen YH; Tsai MC; Hu TH; Hung CH; Chen CH; Kuo YH
    Kaohsiung J Med Sci; 2023 Dec; 39(12):1233-1242. PubMed ID: 37843189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy.
    Zhang L; Liu Y; Song S; Makamure J; Shi H; Zheng C; Liang B
    Infect Agent Cancer; 2024 Apr; 19(1):19. PubMed ID: 38693564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
    J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment.
    Wu DD; He XF; Tian C; Peng P; Chen CL; Liu XH; Pang HJ
    World J Gastroenterol; 2022 Jul; 28(26):3232-3242. PubMed ID: 36051348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
    Gong WF; Zhong JH; Lu SD; Wang XB; Zhang QM; Ma L; Zhang ZM; Xiang BD; Li LQ
    Oncotarget; 2017 Feb; 8(9):15047-15056. PubMed ID: 28122361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
    Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment.
    Lee IC; Lee PC; Chao Y; Chi CT; Wu CJ; Hung YP; Su CW; Hou MC; Huang YH
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hepatitis B reactivation after treatment for HBV-related hepatocellular carcinoma: comparative analysis of radiofrequency ablation versus hepatic resection].
    Liu F; Dan J; Zhang Y; Chen M; Huang J; Xie R
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jan; 22(1):38-42. PubMed ID: 24721242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.
    Jang JW
    World J Gastroenterol; 2014 Jun; 20(24):7675-85. PubMed ID: 24976705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Lim S; Han J; Kim GM; Han KH; Choi HJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW; Ke K; Yan LY; Chen R; Huang JY
    Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
    Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
    Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
    Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
    Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma.
    Jang JW; Kim YW; Lee SW; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK; Chung KW
    PLoS One; 2015; 10(3):e0122041. PubMed ID: 25894607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.